Santa Clara, CA (Vocus/PRWEB) March 28, 2011
Lumenis Ltd., the world's largest medical laser company developing, manufacturing and distributing a broad range of high-end medical lasers and sophisticated energy delivery equipment for surgical, ophthalmic and aesthetic applications, today announced that results from several clinical investigations will be presented at the 31st Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS) from March 30 - April 3, 2011.
The ASLMS Annual Conference provides an opportunity for multidisciplinary physicians to share new scientific developments and clinical applications in light based and related technologies, particularly surgical laser systems.
"This year's conference may be especially important for people who suffer from burn scars," said Rox Anderson, MD, Professor of Dermatology at Harvard Medical School. "Our understanding of how to use laser technologies, alone and in combination with other therapies, is rapidly advancing. It appears that ablative fractional laser and medical treatment are synergistic."
Ronald Moy, MD, one of the leading Dermatologists and Cosmetic Surgeons in Beverly Hills, California, will present results from his recent research, the first of its kind, which studies the histological characteristics of mature burn scars before and after treatment with Lumenis’ UltraPulse fractional CO2 laser.
“This research, although investigational, is a critical step in our understanding of scar revision,” said Dr. Moy, “Improved survival rates for burn victims have created an important need for patients living with painful physical and emotional scars.”
Lumenis has been developing laser and light-based technology for more than four decades and is committed to important research and development causes through the collaborative efforts of the world’s leading medical physicians and facilities.
“Research is not simply about creating new products, it’s about creating solutions that weren’t possible before,” said Robert Mann, General Manager Global Aesthetics and Dermatology at Lumenis. "Our technology is the bridge between research discoveries and practical treatment applications, and we are honored to be working in collaboration with the best minds and research institutions to better develop and utilize laser technology."
The conference will cover topics relevant to a wide range of applications and investigation treatments using Lumenis’ laser technology, including:
Fri., April 1:
Histologic Characteristics Of Mature Burn Scars Before And After Three Treatments With Fractional CO2 Laser - David Ozog, Marsha Chaffins, Ronald Moy, Elizabeth Farhat,Henry Ford Hospital, Detroit, MI, University of California, Los Angeles, CA.
Treatment Of Scars Using Laser And Laser Assisted Corticosteroid Delivery* - Jill Waibel, Stephen Davis, Emmy Graber, Nathan Uebelhoer, Miami Dermatology and Laser Institute, Miller School of Medicine, University of Miami, Miami, FL, Boston University School of Medicine and Boston Medical Center, Boston, MA, Naval Medical Center, San Diego, CA.
Sat., April 2:
Casualties Of War: How Do We Treat Burn And Traumatic Scars? - Jill S. Waibel, Dr. Jill Waibel Laser Center, Miami, FL; R. Rox Anderson, Massachusetts General Hospital, Boston, MA.
A Pilot Study of Laser Assisted Delivery of Allogenic Mesenchymal Stem Cells* - Evangelos Badiavas, Stephen Davis, Jill Waibel, Miller School of Medicine, University of Miami, Cutaneous Surgery Wound Healing Research Laboratory, Miami Dermatology and Laser Institute, Miami, FL.
Effects Of Deviation from Focal Plane on Lesion Depth and Diameter For Ablative Fractional Photothermolysis - Garuna Kositrana, Henry Chan, Dieter Manstein,Wellman Center for Photomedicine, Boston, MA.
Severe Rhinophyma: Fractional CO2 Laser – A New Treatment Option - Rafael Nunes, Daniela Nunes, Luciana Camara, Fabiana Wanick, Guilherme Nunes, Aana Paula Martins, Thiara Lenzi, Slim Clinique Laser Center and Bonsuesso Dermatology Hospital, Rio Di Janeiro, Brazil.
Sun., April 3:
Burns And Trauma Expert Panel - Directors: Lt. Col. (Dr.) Chad Hivnor, Jill S. Waibel, M.D. Faculty: R. Rox Anderson, M.D., Robert J. Spence, M.D.
Ablative Fractional Resurfacing Of Eyelids: A Prospective Evaluation - Brian Biesman, Nashville Centre for Laser and Facial Surgery, Nashville, TN.
Microscopic Observation of Ultrapulse-MODE vs. Superpulse-Mode Fractional CO2 Laser On Back Skin - Yuan-Hong Li, Xue-Gang Xu, Hong-Duo Chen, No. 1 Hospital of China Medical University, Shenyang, China.
Clinical Evaluation of a 800nm Long-Pulsed Diode Laser Device With A Large Spot Size And Vacuum-Assisted Suction For Hair Removal - Omar Ibrahimi, Suzanne Kilmer, UC Davis Medical Center, Skin and Laser Center of Northern California, Sacramento, CA.
The Safety and Efficacy Of Micro Ablative Fractional CO2 Laser In The Treatment Of Non-Facial Skin Photodamage, Wrinkles, Pigment Disorders And Laxity: A Case Series Of 480 Brazilian Patients - Guilherme Almeida, Elaine Marques, Leticia Almeida, Rachel Queiroz,Hospital Sirio Libanes, São Paulo, Brazil.
Melasma Treatment With A Combination Of Topical Creams And Pulsed Co2 Fractional Ablative Resurfacing* - Mario Trelles, Mariano Velez, Instituto Medico Vilafortuny, Cambrils, Tarragona, Spain.
*Above mentioned presentations may contain off-label use conditions, which have not been approved or cleared by the FDA, with product usage under physician “practice of medicine” discretion and professional judgment.
Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has 270 registered patents, over 260 FDA clearances, an installed base of over 30,000 systems and a presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning "Light of Life" highlighting the light, which is the basis of our technologies, used to enhance life. For more information about Lumenis and its products, please visit: http://www.lumenis.com.
For further information contact:
Director of Corporate Communications
# # #